Gradual Recovery to Continue; Maintain Buy

Est. Vs. Actual for Q4FY24: Revenue - MISS; EBITDA - BEAT; PAT - MISS

Changes in Estimates post Q4FY24

FY25E/FY26E: Revenue: -7%/-9%; EBITDA: -6%/-5%; PAT: -10%/-7%

Recommendation Rationale

- Subdued Performance: The company's revenue de-grew by ~2% YoY to Rs 747 Cr, owing to the decline in overall volumes, down 4% YoY. However, this was partly offset by improved realisation by 3% YoY. Moreover, the company reported a beat on EBITDA which grew by 2% YoY to Rs 120 Cr while margins stood at 16.1%, up 68 bps YoY. This was led by sharp improvement in gross margins which were up 812bps YoY to 60.3% on account of lower RM and improved realisation.
- Initiating a direct connect program: To establish a direct connection with consumers and regulate discounts, the company has initiated the sale of products on online marketplaces, functioning as the "Brand As Seller," and through its official websites. Furthermore, the company has also taken major digital initiatives, where the retailers can directly connect with the company through the "Relaxo Parivaar" app. Currently, 50,000 outlets are connected through this app. Moreover, the company has come up with a Distributor Management System to help the distributors for secondary sales to retailers.
- Well-placed for growth: We believe the worst is behind the company as 1)
 Demand environment is likely to pick up in the coming quarters with good monsoons, especially in rural, 2) softening/stable raw material prices will aid gross margin expansion, 3) The company is regaining its the lost market share from unorganised players as more sales are in open footwear, 4) BIS implementation will give better footing to organised players, and 5) It is focusing more on premiumisation by increasing the share of a fast-growing sports and athleisure category.

Sector Outlook: Positive

Company Outlook & Guidance: We maintain our BUY rating on the stock as we roll over our estimates to Mar-26.

Current Valuation: 60x Mar'26 EPS (Earlier Valuation: 60xDec-25 EPS)

Current TP: Rs 950/share (Earlier TP: No change)

Recommendation With a 12% upside potential from the CMP, we maintain our BUY rating on the stock.

Valuation & Recommendation: We maintain our BUY rating on the stock as we roll over our estimates to Mar-26 and maintain our TP of Rs 950/share.

Key Financials (Standalone)

(Rs Cr)	Q4FY24	QoQ (%)	YoY (%)	Axis Est.	Variance (%)
Net Sales	747	4.8	-2.3	758	-1.5
EBITDA	120	38.1	2.0	117	2.9
EBITDA Margin (%)	16.1	388 bps	68 bps	15.4	69 bps
Net Profit	61	59.2	-3.0	59	4.3
EPS (Rs)	2.6	59.2	-3.0	2.5	4.3

Source: Company, Axis Research

(CM	P as of 10 th May 2024)
CMP (Rs)	851
Upside /Downside (%)	12%
High/Low (Rs)	974/762
Market cap (Cr)	21190
Avg. daily vol. (6m) '000 Shrs	99.9
No. of shares (Cr)	25

Shareholding (%)

	Sep-23	Dec-23	Mar-24
Promoter	71.3	71.3	71.3
FIIs	3.2	3.4	3.3
MFs / UTI	8.5	8.8	9.3
Fls/Banks	0.0	0.0	0.0
Others	17.0	16.5	16.1

Financial & Valuations

Y/E Mar (Rs Cr)	FY24E	FY25E	FY26E
Net Sales	2,914	3,389	4,018
EBITDA	407	516	657
Net Profit	200	286	391
EPS (Rs)	8.1	11.5	15.7
PER (x)	105.4	73.9	54.1
EV/EBITDA (x)	51.2	40.1	31.2
RoE (%)	10.2	13.2	15.8

Change in Estimates (%)

Y/E Mar	FY25E	FY26E
Sales	-7%	-9%
EBITDA	-6%	-5%
PAT	-10%	-7%


ESG disclosure Score**

Environmental Disclosure	17.12
Social Disclosure Score	16.05
Governance Disclosure Score	66.07
Total ESG Disclosure Score	33.13
Sector average	41.61

Source: Bloomberg, Scale: 0.1-100

**Note: This score measures the amount of ESG data a company reports publicly and does not measure the company's performance on any data point. All scores are based on 2022 disclosures

Relative performance



Source: Ace Equity, Axis Securities

PreeyamTolia

Research Analyst email: preeyam.tolia@axissecurities.in

SuhaneeShome

Research Associate

email: suhanee.shome@axissecurities.in



Financial Performance

The company's revenue de-grew 2% YoY due to a decline in overall volume (down 4% to 5 Cr pairs). However, this was partly offset by improved average realisation which was up 3% YoY. Its EBITDA grew by 2% YoY to Rs 120 Cr while margins stood at 16.1%, up 68bps YoY. This was led by sharp improvement in gross margins, up 812bps YoY to 60.3% on account of lower RM and improved realisation. PAT de-grew by 3% YoY to Rs 61 Cr in Q4FY24.

Outlook

The company delivered a subdued performance in Q4FY24. However, the management's outlook for FY25 gives us confidence that the worst is behind us and the company is on the right track now. This will led by the following attributes – 1) Expecting a double-digit growth in the coming years, 2) The demand environment is likely to recover in FY25 with good monsoons, especially in rural, 3) Raw material prices are now stable, which will aid in gross margins expansion, 4) The company is regaining its lost market share from unorganised players, 5) BIS Implementation will give better footing to organised players, and 6) It is focusing more on premiumisation by increasing the share of a fast-growing sports and athleisure category.

Other Key Concall Highlights

- Capex: The company has incurred a total capex of Rs 248 Cr, including a land purchase of 30 acres in Bhiwadi, Rajasthan, worth Rs 7Cr.
- Closed/Open Footwear: Volume has grown in open footwear; however, value-wise both are the same. Meanwhile, the management believes that going ahead, closed footwear (Sparx) will grow faster than the open category. Currently, brand-wise, volume is 14% from Sparx, 38% from Flite and 48% from Relaxo/Bahamas.
- Focussing on distribution expansion: The management has guided that they are focusing on reaching 1,00,000 outlets in FY25. Currently, they have 70,000+ retailers/multi-brand outlets. In EBOs, it further added 50-60 more outlets. At present, it has 405 Exclusive Brand Outlets (EBOs).

Key Risks to our Estimates and TP

Increase in competitive intensity, prolonged demand recovery, RM inflation

Change in Estimates

	0	ld	New		% change	
	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Revenue	3,639	4,397	3,389	4,018	-7%	-9%
EBITDA	552	691	516	657	-6%	-5%
PAT	317	421	286	391	-10%	-7%
EPS	12.8	16.9	11.5	15.7	-10%	-7%



Results Review

Rs Cr	Q4FY23	Q3FY24	Axis Sec Est	Q4FY24	YoY (%)	QoQ %	Axis Sec Var
Net Sales	765	713	758	747	(2.3)	4.8	(1.5)
Gross Profit	399	406	422	450	12.9	10.9	6.8
Gross Margins %	52.2	57.0	55.6	60.3	812 bps	328 bps	467 bps
Staff Cost	85.4	96.0	89.6	99.9	17.0	4.0	11.5
Other Operating expenses	195.6	223.0	215.2	230.1	17.6	3.2	6.9
EBITDA	118	87	117	120	2.0	38.1	2.9
EBITDA margins (%)	15.4	12.2	15.4	16.1	68 bps	388 bps	69 bps
Depreciation	33	38	38	38	17.4	2.6	1.5
Interest	4	5	5	5	12.8	(3.5)	(4.5)
Other Income	4	6	5	5	17.1	(15.5)	11.6
PBT	85	51	79	82	(3.7)	61.9	4.5
Tax (incl deferred)	22	12	20	21	(5.5)	70.5	5.4
PAT	63	39	59	61	(3.0)	59.2	4.3
PAT margins (%)	8.3	5.4	7.8	8.2	-6 bps	280 bps	45 bps
EPS	2.6	1.6	2.5	2.6	(3.0)	59.2	4.3



Financials (Standalone)

Profit & Loss (Rs Cr)

Y/E Mar, Rs Cr	FY23	FY24A	FY25E	FY26E
Net sales	2,783	2,914	3,389	4,018
Growth, %	4.9	4.7	16.3	18.6
Other operating income	0	0	0	0
Total income	2,783	2,914	3,389	4,018
Raw material expenses	-1,334	-1,220	-1,403	-1,627
Employee expenses	-343	-389	-467	-551
Other Operating expenses	-769	-899	-1,003	-1,182
EBITDA (Core)	336	407	516	657
Growth, %	(19.2)	21.1	27.0	27.3
Margin, %	12.1	14.0	15.2	16.4
Depreciation	-125	-147	-151	-158
EBIT	211	259	365	499
Growth, %	(30.3)	23.0	41.1	36.6
Margin, %	7.6	8.9	10.8	12.4
Other Income	19	29	38	45
Non-recurring Items	0	0	0	0
Pre-tax profit	210	269	384	525
Tax provided	-56	-69	-98	-134
Profit after tax	154	200	286	391
Growth, %	(33.6)	29.8	42.7	36.7
Net Profit (adjusted)	154	200	286	391
Unadj. shares (Cr)	25	25	25	25
Wtdavg shares (Cr)	25	25	25	25

Source: Company, Axis Securities

Balance Sheet (Rs Cr)

As of 31st Mar, Rs Cr	FY23	FY24E	FY25E	FY26E
Cash & bank	74	108	209	440
Debtors	270	283	329	390
Inventory	564	590	687	814
Loans & advances	1	1	1	1
Other current assets	84	84	84	84
Total current assets	1,194	1,267	1,510	1,929
Investments	25	25	25	25
Gross fixed assets	1,692	1,892	2,042	2,142
Less: Depreciation	-542	-689	-840	-999
Add: Capital WIP	89	89	89	89
Net fixed assets	1,239	1,292	1,291	1,232
Non-current assets	37	37	37	37
Total assets	2,495	2,620	2,862	3,224
Current liabilities	471	483	526	583
Provisions	19	19	19	19
Total current liabilities	490	502	545	602
Non-current liabilities	150	150	150	150
Total liabilities	640	652	695	752
Paid-up capital	25	25	25	25
Reserves & surplus	1,830	1,944	2,143	2,447
Shareholders' equity	1,855	1,969	2,168	2,472
Total equity & liabilities	2,495	2,620	2,862	3,224



Cash Flow (Rs Cr)

FY23	FY24E	FY25E	FY26E
210	269	384	525
125	147	151	158
99	-27	-99	-131
-54	-69	-98	-134
380	321	338	418
-228	-200	-150	-100
-31	0	0	0
-259	-200	-150	-100
121	121	188	318
76	0	0	0
-62	-87	-87	-87
14	-87	-87	-87
135	34	101	231
	210 125 99 -54 380 -228 -31 -259 121 76 -62 14	210 269 125 147 99 -27 -54 -69 380 321 -228 -200 -31 0 -259 -200 121 121 76 0 -62 -87 14 -87	210 269 384 125 147 151 99 -27 -99 -54 -69 -98 380 321 338 -228 -200 -150 -31 0 0 -259 -200 -150 121 121 188 76 0 0 -62 -87 -87 14 -87 -87




Ratio Analysis (%)

As of 31st Mar, Rs Cr	FY23	FY24E	FY25E	FY26E
Per Share data				
EPS (INR)	6.2	8.1	11.5	15.7
Growth, %	(33.6)	29.8	42.7	36.7
Book NAV/share (INR)	74.7	79.3	87.3	99.5
FDEPS (INR)	6.2	8.1	11.5	15.7
CEPS (INR)	11.3	14.0	17.6	22.1
CFPS (INR)	15.5	11.7	12.1	15.0
DPS (INR)	2.5	3.5	3.5	3.5
Return ratios				
Return on assets (%)	7.1	8.6	11.1	13.5
Return on equity (%)	8.3	10.2	13.2	15.8
Return on capital employed (%)	8.8	10.5	13.6	16.5
Turnover ratios				
Asset turnover (x)	1.8	1.8	2.0	2.3
Sales/Total assets (x)	1.1	1.1	1.2	1.3
Sales/Net FA (x)	2.3	2.3	2.6	3.2
Working capital/Sales (x)	0.2	0.2	0.2	0.2
Receivable days	35.5	35.5	35.5	35.5
Inventory days	73.9	73.9	73.9	73.9
Payable days	37.7	38.5	39.1	39.7
Working capital days	58.8	59.6	61.9	64.2
Liquidity ratios				
Current ratio (x)	2.5	2.6	2.9	3.3
Quick ratio (x)	1.3	1.4	1.6	1.9
Interest cover (x)	11.0	13.9	19.5	26.4
Dividend cover (x)				
Total debt/Equity (%)	-	-	-	-
Valuation				
PER (x)	136.8	105.4	73.9	54.1
PEG (x) - y-o-y growth	(4.1)	3.5	1.7	1.5
Price/Book (x)	11.4	10.7	9.8	8.6
EV/Net sales (x)	7.5	7.1	6.1	5.1
EV/EBITDA (x)	62.1	51.2	40.1	31.2
EV/EBIT (x)	99.0	80.4	56.7	41.1



Relaxo Footwears Price Chart and Recommendation History



Date	Reco	TP	Research
31-Jan-22	BUY	1,350	Result Update
16-May-22	BUY	1,120	Result Update
28-Jul-22	BUY	1,120	Result Update
04-Nov-22	HOLD	950	Result Update
06-Feb-23	HOLD	850	Result Update
15-May-23	BUY	980	Result Update
01-Jun-23	BUY	990	Top Picks
01-Jul-23	BUY	990	Top Picks
25-Jul-23	BUY	1,050	Result Update
01-Aug-23	BUY	1,050	Top Picks
01-Sep-23	BUY	1,050	Top Picks
03-Oct-23	BUY	1,050	Top Picks
01-Nov-23	BUY	1,050	Top Picks
06-Nov-23	BUY	1,020	Result Update
01-Dec-23	BUY	1,020	Top Picks
01-Jan-24	BUY	1,020	Top Picks
02-Feb-24	BUY	950	Result Update
13-May-24	BUY	950	Result Update

Source: Axis Securities



About the analyst



Analyst: Preeyam Tolia

Contact Details: preeyam.tolia@axissecurites.in

Sector: FMCG & Retail

Analyst Bio: Preeyam Tolia is MBA Finance and CFA Level 1 and part of the Axis Securities Research

Team

About the analyst



Analyst: Suhanee Shome

Contact Details: suhanee.shome@axissecurites.in

Sector: FMCG & Retail

Analyst Bio: Suhanee Shome is MBA and part of the Axis Securities Research Team

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

- 1. Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH000000297. ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.
- 2. ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity.
- 3. ASL has no material adverse disciplinary history as on the date of publication of this report.
- 4. I/We, Preeyam Tolia (MBA & CFA L1) and Suhanee Shome (MBA) hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We (Research Analyst) also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associate does not have any material conflict of interest. I/we have not served as director / officer, employee etc. in the subject company in the last 12-month period.Any holding in stock No
- 5. ASL has not received any compensation from the subject company in the past twelve months. ASL has not been engaged in market making activity for the subject company.
- 6. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have:

Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or; Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report; ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report.

Term& Conditions:

This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report.



DEFINITION OF RATINGS		
Ratings	Expected absolute returns over 12-18 months	
BUY	More than 10%	
HOLD	Between 10% and -10%	
SELL	Less than -10%	
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning valuation and recommendation	
UNDER REVIEW	UNDER REVIEW We will revisit our recommendation, valuation and estimates on the stock following recent events	
NO STANCE	We do not have any forwardlooking estimates, valuation or recommendation for the stock	

Disclaimer:

Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advice necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document.

ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. The Research reports are also available & published on AxisDirect website.

Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

Copyright in this document vests with Axis Securities Limited.

Axis Securities Limited, SEBI Single Reg. No.- NSE, BSE & MSEI – INZ000161633, ARN No. 64610, CDSL-IN-DP-CDSL-693-2013, SEBI-Research Analyst Reg. No. INH 000000297, SEBI Portfolio Manager Reg. No.- INP000000654, Main/Dealing off.- Axis Securities Ltd, Unit No.1001, 10th Floor, Level-6, Q2 Building, Aurum, Q Parc, Plot No. 4/1, TTC, Thane – Belapur Road, Ghansoli, Navi Mumbai. – 400 710., Regd. off.- Axis House,8th Floor, Wadia International Centre, PandurangBudhkar Marg, Worli, Mumbai – 400 025. Compliance Officer: Jatin Sanghani, Email: compliance.officer@axisdirect.in, Tel No: 022-49212706.